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SHOULD OUR GENES BE PART OF THE PATENT 
BARGAIN? MAXIMIZING ACCESS TO MEDICAL 
DIAGNOSTIC ADVANCES WHILE ENSURING RESEARCH 
REMAINS PROFITABLE 
Johanna Jacob† 
I. INTRODUCTION 
The purpose of the United States patent system is “[t]o promote 
the Progress of Science and useful Arts.”1 Currently, there is a heated 
emotional debate about whether patents directed to genetic sequences 
promote or hinder the progress of science, a debate which may soon 
find its way to the United States Supreme Court.
2
 Unfortunately, the 
debate is too often characterized in terms of policy concerns. In 
Association for Molecular Pathology v. United States Patent and 
Trademark Office, Judge Sweet broke with three decades of United 
States Patent and Trademark Office (USPTO) precedent,
3
 declaring 
the method and system claims to the genetic sequences of BRCA1 
                                                                                                                            
 †  Johanna Jacob, Santa Clara Law Student, J.D. Expected May 2012. This comment 
was selected as the winner of the 2010-2011 Santa Clara Computer & High Technology Law 
Journal Comment Competition. 
 ††  As this issue went to press, the Supreme Court released its opinion in the Mayo v. 
Prometheus case. Mayo Collaborative Servs. v. Prometheus Labs., Inc., No. 10-1150, slip op. 
(U.S. Mar. 20, 2012), available at http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf.  
Shortly after, in the Molecular Pathology v. Myriad Genetics case the Supreme Court granted 
the petition for certiorari, vacated the Federal Circuit judgment, and remanded for 
reconsideration in light of the Prometheus decision. Cert. Summ. Dispositions at 2, Ass’n for 
Molecular Pathology v. Myriad Genetics, No. 11-725 (U.S. Mar. 26, 2012) (previously entitled 
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office). 
 1. U.S. CONST. art. I, § 8, cl. 8. 
 2. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 
2d 181, 185 (S.D.N.Y. 2010), aff’d in part, rev’d in part, 653 F.3d 1329 (Fed. Cir. 2011); see 
also Liberate the Breast Cancer Genes, AM. CIVIL LIBERTIES UNION (Mar. 29, 2010), 
http://www.aclu.org/free-speech_womens-rights/liberate-breast-cancer-genes (varying opinions 
on the patentability of genetic sequences). 
 3. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1367 (Fed. Cir. 2011) (Moore, J., concurring) (“Even before the current guidelines formalized 
the Patent Office’s position, however, it granted patents to human genes in the early 1980s, and 
subsequently issued thousands of patents on ‘isolated DNA.’”). 
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and BRCA2 ineligible for patents.
4
 Judge Sweet created a blanket 
exception to 35 U.S.C. §101 by characterizing genes under the “law 
of nature” exception to patentability.5 Myriad Genetics Inc. (Myriad) 
appealed, and the Federal Circuit Court of Appeals ruled on July 29, 
2011.
6
 The Federal Circuit reversed Judge Sweet’s ruling by 
upholding claims directed to isolated genetic sequences as subject 
matter eligible for patenting under 35 U.S.C. §101.
7
 However, the 
Federal Circuit invalidated diagnostic method claims that merely 
compared a genetic sequence to an individual’s native genetic 
sequence as an abstract mental process.
8
 Both parties filed a petition 
for rehearing in the Federal Circuit.
9
 
The real issue in Association for Molecular Pathology is patient 
access to health care, which should not be achieved through a 
judicially-created exception to the statutory definition of patent 
eligible subject matter. While the Federal Circuit focuses on the 
science, the underlying issues largely guide their interpretation. It is 
unlikely that agreement on the science and how it applies to patent 
eligible subject matter will ever be achieved. Judge Moore, in his 
concurring opinion, rightly states that it is the policy that tips the 
scales towards patentability.
10
 
Weakening biotechnology patent law by declaring claims to 
genetic sequences patent ineligible, as products of nature under 35 
U.S.C. §101, would negatively impact patient access to biotechnology 
advances by decreasing the incentive of investors to enter the market 
more than it could possibly help promote patient access to BRCA1 
                                                                                                                            
 4. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 185. 
 5. Id. at 237 (“As determined above, the patents issued by the USPTO are directed to a 
law of nature and were therefore improperly granted.”). 
 6. Ass’n for Molecular Pathology, 653 F.3d at 1329. 
 7. Id. at 1334. 
 8. Id. at 1334. 
 9. Plaintiffs-Appellees’ Petition for Panel Rehearing, Ass’n for Molecular Pathology v. 
U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 
5057016; Defendants-Appellants’ Petition for Panel Rehearing, Ass’n for Molecular Pathology 
v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 
5057015. 
 10. Ass’n for Molecular Pathology, 653 F.3d at 1367 (Moore, J., concurring) (“I believe 
we must be particularly wary of expanding the judicial exception to patentable subject matter 
where both settled expectations and extensive property rights are involved. Combined with my 
belief that we should defer to Congress, these settled expectations tip the scale in favor of 
patentability.”). 
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and BRCA2 diagnostic technologies. Patient access to second 
opinions, affordable diagnostic technologies, patient counseling, 
comprehensive genetic testing, and insurance coverage are not aspects 
of patent law, and are best addressed through meaningful health care 
reform. 
II. BACKGROUND 
A. 35 U.S.C. §101 Patentable Subject Matter 
Patentable subject matter, the threshold test for patentability, is 
defined as “any new and useful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof.”11 
The statute on patentable subject matter, 35 U.S.C. §101, is given 
broad meaning through the use of the word “any” in describing the 
type of new and useful processes that are patentable, the legislative 
history surrounding its enactment, and the interpretation that 
“anything under the sun that is made by man” is patentable.12 The 
proper forum for excluding a specific subject matter from the patent 
bargain lies with Congress in the legislative body and not the 
judiciary.
13
 
However, courts recognize some subject matter as ineligible for 
patentability under 35 U.S.C. §101. Exceptions to patentable subject 
matter include laws of nature, physical phenomena, and abstract 
ideas.
14
 Products of nature should be “free to all men and reserved 
exclusively to none.”15 Laws of nature, physical phenomena, and 
abstract ideas are recognized as a type of scientific discovery, rather 
than a novel invention. This promotes the policy that a discovery is 
left to the public domain while an invention benefits from intellectual 
                                                                                                                            
 11. 35 U.S.C. § 101 (2006). 
 12. 35 U.S.C. § 101 (2006); Diamond v. Chakrabarty, 447 U.S. 303, 307-309 (1980). 
 13. See Chakrabarty, 447 U.S. at 318. 
Our task, rather, is a narrow one of determining what Congress meant by the 
words it used in the statute; once that is done our powers are exhausted. Congress 
is free to amend §101 so as to exclude from patent protection organisms 
produced by genetic engineering. . . . But, until Congress takes such action, this 
Court must construe the language of §101 as it is. 
Id. 
 14. Id. at 309. 
 15. Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948). 
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property rights.
16
 
The line between scientific discovery and invention blurs when 
patent law and biotechnology intersect. In 1948, the Supreme Court 
held a combination fertilizer with several different naturally occurring 
bacteria unpatentable, because a natural material, even if combined in 
a novel fashion, will still be ineligible for patentability if the 
functionality of the material would occur naturally.
17
 Later, in 
Chakrabarty, the Supreme Court held that a genetically modified 
bacterium engineered to break down crude oil is a “non[-]naturally 
occurring manufacture or composition of matter” and therefore 
patentable.
18
 The test articulated in Chakrabarty was whether the non-
naturally occurring composition of matter was a product of human 
ingenuity with “distinctive name, character and use.”19 Therefore a 
composition of matter must be: (1) non-naturally occurring; (2) 
product of ingenuity; with (3) distinctive name, character and use.
20
 In 
finding that the bacteria met that standard of law, the court remarked 
that the patentee had produced a new bacterium with “markedly 
different characteristics” from the product as it occurred in nature, 
with the potential for significant utility.
21
 After Chakrabarty, patents 
on genetic sequences were held to be patentable and over 4,000 
patents on genes were issued.
22
 
The Supreme Court addressed the patentability of an isolated 
substance in The American Wood-Paper Co v. Fibre Disintegrating 
Co.
23
 The Court held purified cellulose is a mere “extract” and is not a 
new manufacture subject to patentability.
24
 In contrast, the 
patentability of a purified naturally-occurring biological compound 
was addressed by a district court in New York in 1912.
25
 Judge 
                                                                                                                            
 16. See Parker v. Flook, 437 U.S. 584, 593 (1978). 
 17. Funk Bros., 333 U.S. at 131. 
 18. Chakrabarty, 447 U.S. at 309-10. 
 19. Id. at 309-10. 
 20. Id. 
 21. Id. at 310. 
 22. Denise Caruso, A Challenge to Gene Theory, a Tougher Look at Biotech, N.Y. TIMES 
(July 1, 2007), 
https://www.nytimes.com/2007/07/01/business/yourmoney/01frame.html?pagewanted=all. 
 23. Am. Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. (23 Wall.) 566, 593-94 
(1874). 
 24. Id. at 594. 
 25. Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911), aff’d 
in part, rev’d in part, 196 F. 496 (2d Cir. 1912). 
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Learned Hand found isolated purified adrenaline to be patentable.
26
 A 
purified base form of a component was found to be a new thing, both 
therapeutically and chemically, because it functioned differently in its 
purified form than it did in nature.
27
 Currently, courts follow Judge 
Hand’s 1912 ruling in Parke-Davis for guidance on the patentability 
of isolated, naturally-occurring biological substances.
28
 
B. What Are Genes? 
“Genes are the ‘basic units of heredity’ that enable organisms to 
transmit to future generations the blueprint for all proteins.”29 Genes 
contain the hidden plans and design for development of an 
organism.
30
 Deoxyribonucleic acid (DNA) is the carrier of genetic 
information, and it is a long unbranched polymer composed of four 
bases: adenine, cytosine, guanine, and thymine.
31
 The bases are 
attached to a repetitive sugar phosphate chain through chemical 
bonds, like beads strung to a necklace.
32
 DNA normally exists as a 
two-strand “double helix.”33 Each base is bound to its complementary 
base pair, A-T ad G-C. Therefore, when the double helix splits, each 
strand of the double helix can create its own copy of the original 
double helix.
34
 The linear order of the nucleotide bases (A, T, G and 
C) is referred to as the genetic sequence.
35
 The human genetic 
sequence would fill a book of more than 500,000 pages written in the 
four-letter genetic alphabet.
36
 
The sections of the DNA strand that encode to form proteins or 
functional molecules are known as genes; not every part of the DNA 
                                                                                                                            
 26. Id. 
 27. Id. 
 28. Lisa Larrimore Ouellette, Note, Access to Bio-Knowledge: From Gene Patents to 
Biomedical Materials, 2010 STAN. TECH. L. REV. ¶ 13 (2010). 
 29. Brief for the United States as Amicus Curiae Supporting Neither Party, Ass’n for 
Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 
2010-1406), 2010 WL 4853320. 
 30. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 98 (3d ed. 1994). 
 31. Id. 
 32. Id. at 98-99. 
 33. See id. at 99. 
 34. Id. at 102. 
 35. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1336 (Fed. Cir. 2011). 
 36. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 102 (3d ed. 1994). 
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strand codes for a gene.
37
 The human genome contains approximately 
3 billion base pairs, and almost every cell in the human body contains 
a complete genome.
38
 Human DNA is arranged into 24 distinct 
chromosomes, which are physically separate molecules ranging in 
length from 50-250 million base pairs, with each chromosome 
containing many genes.
39
 There are approximately 20,000-25,000 
genes, which together contain the physical and functional traits that 
form a human being.
40
 
Ribonucleic Acid (RNA) is like DNA, in that it is a chain of 
linked nucleotides.
41
 However, the RNA molecule is single stranded, 
composed of the sugar ribose instead of deoxyribose, and consists of 
the nucleotides adenine, guanine, uracil (which replaces the thymine 
found in DNA) and cytosine.
42
 Messenger RNA (mRNA) is a type of 
RNA that transfers the information about DNA’s amino acid 
sequence to the protein synthesis process.
43
 Complementary DNA 
(cDNA) is a molecule generated from mRNA through “reverse 
transcription.”44 Each base in the cDNA is complementary to the 
corresponding base in the mRNA it is generated from; and therefore, 
it contains the same informational content as the original DNA 
molecule. cDNA is typically generated in a laboratory.
45
 Unlike 
DNA, cDNA does not contain the non-coding sequences because they 
                                                                                                                            
 37. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 104 (3d ed. 1994). 
The synthesis of proteins involves copying specific regions of DNA (the genes) 
into polynucleotides of a chemically and functionally different type known as 
ribonucleic acid, or RNA. . . . Molecules of RNA are synthesized by a process 
known as DNA transcription, which is similar to DNA replication in that one of 
the two strands of DNA acts as a template on which the base-pairing abilities of 
incoming nucleotides are tested. 
Id. 
 38. The Human Genome Project, The Science Behind the Human Genome Project: Basic 
Genetics, Genome Draft Sequence, and Post-Genome Science, OAK RIDGE NAT’L LAB., 
http://www.ornl.gov/sci/techresources/Human_Genome/project/info.shtml (last modified Mar. 
26, 2008). 
 39. Id. 
 40. Id. 
 41. RNA Transcription, NOBEL FOUNDATION, 
http://www.nobelprize.org/educational/medicine/dna/b/transcription/rna_strand.html (last visited 
Feb. 28, 2012). 
 42. Id. 
 43. Id. 
 44. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 
181, 198 (S.D.N.Y. 2010). 
 45. Id. 
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were removed in the creation of the mRNA.
46
 
“Isolated DNA” is the result of a laboratory process where the 
DNA molecule is excised from the genome and separated from its 
cellular environment.
47
 Courts typically hold that products of nature 
are different from products that have been altered or enhanced 
through processes of extraction, concentration, and purification of 
natural materials.
48
 Isolation is a form of extraction, which may cause 
genetic sequence patents to cross the line from patent ineligible to 
patentable.
49
 
Although isolation usually tips the scale towards patentability, 
DNA sequencing methods are rapid and reliable.
50
 DNA has become 
the easiest macromolecule of the cell to analyze.
51
 It is currently 
possible to excise a specific region of DNA, produce a virtually 
unlimited amount of copies, and to determine the sequence of the 
nucleotides at a rate of hundreds of nucleotides a day.
52
 In order to 
sequence a gene, a chromosome is first broken into much shorter 
segments through subcloning.
53
 Templates are generated by creating 
fragments that differ in length by a single base, and these fragments 
are then separated by gel electrophoresis.
54
 The final base at the end 
of each fragment is identified, recreating the 4 letter genetic alphabet 
base by base.
55
 As scientists’ knowledge of this process and 
capabilities rapidly evolved, patent applications on human genes were 
                                                                                                                            
 46. Id. 
 47. Brief for the United States as Amicus Curiae Supporting Neither Party at 3,  
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 
2010) (No. 2010-1406), 2010 WL 4853320, at *3. 
 48. See id. at 35-36. 
 49. See id. 
 50. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 291 (3d ed. 1994). 
From being the most difficult macromolecule of the cell to analyze, DNA has 
become the easiest. It is now possible to excise a specific region of DNA, to 
produce a virtually unlimited number of copies of it, and to determine the 
sequence of its nucleotides at a rate of hundreds of nucleotides a day. 
Id. 
 51. Id. 
 52. Id. 
 53. The Human Genome Project, The Science Behind the Human Genome Project: Basic 
Genetics, Genome Draft Sequence, and Post-Genome Science, OAK RIDGE NAT’L LAB., 
http://www.ornl.gov/sci/techresources/Human_Genome/project/info.shtml (last modified Mar. 
26, 2008). 
 54. Id. 
 55. Id. 
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filed in increasing numbers.
56
 
III. ASSOCIATION FOR MOLECULAR PATHOLOGY V. U.S. PATENT 
AND TRADEMARK OFFICE: THE CONTROVERSY AND 
UNDERLYING ISSUES 
Myriad’s patents are controversial for several reasons. First, 
Myriad’s patents deal with breast cancer—a widespread disease that 
crosses all racial and socioeconomic groups.
57
 Second, Myriad’s 
business plan relies on stringent enforcement of their patent rights, 
leaving them the sole provider of an important diagnostic test.
58
 
Myriad’s business practices also caused issues relating to patient 
access, treatment, and counseling.
59
 Third, negative publicity through 
advocacy groups framed the debate as patenting human blueprints.
60
 
The ACLU made a tactical decision to attack patentability, rather than 
frame this issue in terms of patient health care reform, which would 
have addressed patient concerns without implicating long standing 
patent law policies.
61
 
A. BRCA1 and BRCA2 Are Important Tools in the Diagnosis of 
Breast Cancer and Ovarian Cancer 
Breast cancer is the second most common cancer among women 
in the United States,
62
 with approximately one in eight U.S. women 
developing breast cancer over her lifetime.
63
 Breast cancer is one of 
the leading causes of cancer death among women of all races and 
                                                                                                                            
 56. Jon F. Merz & Mildred K. Cho, What Are Gene Patents and Why Are People Worried 
About Them?, 8 CMTY. GENETICS 203, 204 (Oct. 2005). 
 57. See Breast Cancer Statistics, CTRS. FOR DISEASE CONTROL & PREVENTION (Nov. 23, 
2010), http://www.cdc.gov/cancer/breast/statistics/. 
 58. See E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the Policy 
Storm, 12 GENETICS IN MED. S39, S41-43 (2010). 
 59. See id. at S45-48; see also Complaint at 2, Ass’n for Molecular Pathology v. U.S. 
Patent & Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (No. 1:09-cv-04515-RWS), 
2009 WL 1343027. 
 60. See, e.g., Michael Crichton, Op-Ed., Patenting Life, N.Y. TIMES, Feb. 13, 2007, at 
A23, available at http://www.nytimes.com/2007/02/13/opinion/13crichton.html; Liberate the 
Breach Cancer Genes, supra note 2. 
 61. See Complaint, supra note 59, at 3. 
 62. Breast Cancer Statistics, CTRS. FOR DISEASE CONTROL AND PREVENTION (Nov. 23, 
2010), http://www.cdc.gov/cancer/breast/statistics/. 
 63. See Cancer Among Women, CTRS. FOR DISEASE CONTROL AND PREVENTION (Feb. 
10, 2011), http://www.cdc.gov/cancer/dcpc/data/women.htm. 
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populations in the U.S.
64
 Per year approximately 202,964 women are 
diagnosed with breast cancer and 40,598 women die from it.
65
 
Ovarian cancer is the fifth most common cancer among females in the 
U.S. and it is the leading cause of death among reproductive 
cancers.
66
 
BRCA1 and BRCA2 are important diagnostic tools in the 
treatment of breast cancer and ovarian cancer.
67
 Estimates place breast 
cancer occurrence in a BRCA1 or BRCA2 mutation carrier between 
3% and 10%.
68
 Women with BRCA1 and BRCA2 mutations face up 
to an 85% increased risk of developing breast cancer, and up to 50% 
increased risk of developing ovarian cancer.
69
 Therefore, BRCA1 and 
BRCA2 diagnostics are important tools in prophylactic treatment for 
women with dominantly transmitted BRCA1 and BRCA2 
mutations.
70
 The pervasiveness of breast cancer and ovarian cancer in 
the lives of many Americans sets the emotional back-drop for the 
debate over control of diagnostic technologies surrounding the 
treatment of these diseases. 
B. Myriad’s Business Practices 
Nearly all of the patented genetic sequences relate to genes 
associated with human health, including genes relating to diabetes, 
obesity, and cancer.
71
 The holders of these patents, under U.S. patent 
law, are not required to grant licenses on their patent; however, the 
majority of these patent holders willingly issue licenses to diagnostic 
                                                                                                                            
 64. Breast Cancer Statistics, supra note 62. 
 65. Id. 
 66. Ovarian Cancer, PUBMED HEALTH (Dec. 28, 2010), 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001891/. 
 67. See e.g., id.; BRCA1 and BRCA2: Cancer Risk and Genetic Testing, NAT’L CANCER 
INST. (May 29, 2009), http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. 
 68. Gold & Carbone, supra note 58, at S39. 
Of all cases of breast cancer, the estimates of affected women who are carriers of 
a mutated allele dominantly transmitted and associated with a high risk of breast 
cancer ranges between 5% and 10%. Estimates of breast cancer cases occurring 
in BRCA1 or BRCA2 mutation carriers vary from between 3% and 10%. 
Id. 
 69. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 
181, 203 (S.D.N.Y. 2010). 
 70. See Gold & Carbone, supra note 58, at S39. 
 71. Olga Bogard, Comment, Patenting the Human Body: The Constitutionality of Gene 
Patents and Suggested Remedies for Reform, 63 SMU L. REV. 1319, 1326 (2010). 
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laboratories.
72
 The willing grant of these licenses to diagnostic labs 
results in greater access to diagnostic testing, second opinions, price 
reductions, and acceptance of insurance providers.
73
 Myriad, 
however, chose an “unprecedented [path] in the field of genetic 
testing,” by exercising their legal right to exclude others from using 
their invention on the diagnostic tests relating to a predisposition of 
breast cancer and ovarian cancer in women.
74
 
Marc Skolnick headed Myriad’s “unprecedented path” into the 
successful commercialization of genetic testing. This path began at 
the University of Utah’s Center for Genetic Epidemiology, where 
Marc Skolnick led a team of researchers who were working to 
identify the genetic sequence of BRCA1.
75
 Skolnick’s work relied on 
an extensive database of Mormon families (200,000), which he cross-
referenced with a Utah cancer registry that provided him with 40,000 
cross-linked entries that “spurred much of Myriad’s future 
research”.76 
In 1990, Dr. Skolnick concluded additional resources were 
needed in order to remain competitive with another team of 
researchers who had received a substantial grant from the National 
Institute of Health (NIH).
77
 In 1991, Dr. Skolnick founded Myriad 
through a local venture capital group, with the goal of raising the 
necessary funding to complete his research.
78
 Myriad received 
significant funding from Eli Lilly and Co.; at least $1 million in 
equity and another $1.8 million over three years, the former part of a 
$10 million private stock offering.
79
 Additionally, the NIH 
contributed $5 million to the University of Utah research team.
80
 One 
analysis suggested that the NIH contributed one-third of the funding 
for the identification of BRCA1.
81
 
Myriad’s business model focused on being the leading 
                                                                                                                            
 72. Id. 
 73. Id. 
 74. Id. at 1327. 
 75. Gold & Carbone, supra note 58, at S41. 
 76. Id. 
 77. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 
181, 201 (S.D.N.Y. 2010). 
 78. Id.; Gold & Carbone, supra note 58, at S41. 
 79. Gold & Carbone, supra note 58, at S44. 
 80. Id. 
 81. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 202. 
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biopharmaceutical diagnostic company.
82
 Myriad planned to build a 
strong and successful relationship with providers, laboratories and 
insurers as the go to genetic diagnostic tester.
83
 They wanted to be 
considered a leading market player to be used for future discovered 
genetic testing.
84
 Myriad’s goal was to quickly and effectively 
integrate the diagnostic tests into the market, since they were not 
subject to FDA clinical trials, in order to generate funds for further 
drug discovery.
85
 Although Myriad’s business model may have 
differed from other companies in the health care sector, it was fully 
supported by rights granted under patent law. 
Myriad marketed several different diagnostic tests.
86
 The 
comprehensive test, which provided the full sequence of both BRCA1 
and BRCA2 genes, initially cost $2400.
87
 “Myriad only offered [their] 
testing services through physicians.”88 Myriad relied on genetic 
counselors to screen potential test subjects; however, there were not 
enough genetic counselors to satisfy market demand and Myriad 
ended up having to train and sponsor physicians.
89
 Myriad did not 
require genetic counseling once the patient received the results, 
although the hospital was responsible for signing an informed 
consent.
90
 
Myriad sent cease and desist letters to other laboratories that 
were performing BRCA1 and BRCA2 diagnostic sequencing.
91
 The 
letters specified that the cease and desist notification did not apply to 
research testing for non-commercial research programs where the 
results were not provided to the patient and where no money was 
received in consideration for the test.
92
 Despite Myriad’s business 
plan, Myriad has yet to make a profit from its diagnostic business.
93
 
                                                                                                                            
 82. Gold & Carbone, supra note 58, at S42. 
 83. Id. 
 84. Id. 
 85. Id. 
 86. Id. 
 87. Id. 
 88. Id. 
 89. Id. 
 90. Id. 
 91. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 
2d 181, 187 (S.D.N.Y. 2010). 
 92. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 
1329, 1340 (Fed. Cir. 2011). 
 93. Gold & Carbone, supra note 58, at S47. 
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C. Both the Negative Publicity Surrounding the Patentability of 
Genes and the ACLU’s Complaint, Focused on Patient’s 
Access to Diagnostic Tests and Treatments 
Publicity fueled the public debate, which characterized Myriad 
as owning a patent on a piece of the human body.
94
 Myriad’s patents 
sparked significant newspaper coverage, and the majority of articles 
(77.6%) were negative.
95
 In contrast, only 6.9% were positive and 
only around 50% of the news coverage showed more than one 
perspective.
96
 “The story was primarily framed as a social 
dilemma”97, as evidenced by the ACLU’s many published articles and 
videos.
98
 The ACLU publications included “Tell Congress: My Genes 
Aren’t For Sale” and “Liberate the Breast Cancer Genes.”99 The 
ACLU and other patient advocacy organizations focused on the 
inability of patients to receive second opinions, access the test, and 
the misinformation in the process.
100
 Even science-fiction author 
Michael Crichton in a New York Times opinion piece warned, “You, 
or someone you love, may die because of a gene patent that should 
never have been granted in the first place.”101 
With so many conflicting interests intersecting, the plaintiffs that 
filed the complaint in the Southern District of New York were varied 
and each asserted their own reasons for standing.
102
 The plaintiffs can 
be categorized into four groups: national organizations, doctors, 
patient support and advocacy groups, and individual patients.
103
 
                                                                                                                            
 94. See, e.g., Elizabeth Landau, How Human Genes Become Patented, CNN (May 13, 
2009), http://articles.cnn.com/2009-05-13/health/genes.patent.myriad_1_human-genes-brca1-
trademark-office?_s=PM:HEALTH. 
 95. Timothy Caulfield et al., Myriad and the mass media: the covering of a gene patent 
controversy, 9 GENETICS IN MED. 850, 852 (2007). 
 96. Id. 
 97. Id. at 853. 
 98. See Search Results for Myriad, AM. CIVIL LIBERTIES UNION, 
http://www.aclu.org/search/Myriad?type=blog (last visited Sept. 15, 2011). 
 99. Sandra Fulton, Tell Congress: My Genes Aren’t for Sale, AM. CIVIL LIBERTIES 
UNION (Apr. 27, 2010, 4:37 PM), http://www.aclu.org/blog/free-speech-womens-rights/tell-
congress-my-genes-arent-sale/; Joel Engardio, Liberate the Breast Cancer Genes, AM. CIVIL 
LIBERTIES UNION (May 13, 2009, 8:26 AM), http://www.aclu.org/2009/05/13/liberate-the-
breast-cancer-genes/. 
 100. See Complaint, supra note 59, at 2. 
 101. Crichton, supra note 60. 
 102. See Complaint, supra note 59, at 4-13. 
 103. See id. 
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National organizations asserted that they represented members, some 
of whom are “ready, willing, and able to engage in research and 
clinical practice involving the BRCA1 and BRCA2 genes if the 
patents were invalidated.”104 Individual doctors asserted that they 
were “ready, willing, and able” to engage in testing or utilize 
alternative testing facilities if the patents were invalidated.
105
 Patient 
advocacy groups maintained they would benefit from increased 
research and members would benefit from information provided from 
multiple laboratory testing.
106
 Individual female patients complained 
of the following issues: Myriad’s denial of MassHealth care 
coverage;
107
 increased research into genetic variants of unknown 
significance
108
; availability of a second opinion which would help 
make significant medical decisions; and a need for greater medical 
insurance acceptance and affordability.
109
 
IV. THE CLAIMS AT ISSUE IN ASSOCIATION FOR MOLECULAR 
PATHOLOGY V. U.S. PATENT AND TRADEMARK OFFICE 
There are several types of patent claims on genes. The claims at 
issue in Myriad included: composition of matter, diagnostic, and 
functional uses.
110
 
A. Composition of Matter 
Compositions of matter claims to genetic sequences include the 
isolated and purified genetic sequence and all derivative products.
111
 
This type of claim can include the genetic sequence, the virus or 
vector containing the claimed sequence, transfected cell lines, and the 
                                                                                                                            
 104. Id. at 4-5. 
 105. Id. at 9-10. 
 106. Id. 
 107. Id. at 10. Masshealth is Massachusetts’s public health insurance program for low and 
medium-income residents. See Massachusetts Health Care Program, MASSRESOURCES.ORG, 
http://www.massresources.org/masshealth.html (last visited Feb. 28, 2012). 
 108. There are many variants of the BRCA1/BRCA2 beyond those, which the Myriad 
diagnostic test covered. Some variants of the BRCA1/BRCA2 are still of unknown significance. 
For example, Plaintiff Runi Limary received the result “genetic variant of uncertain 
significance”. She sought the invalidation of Myriad’s patents in order to access additional 
resources for testing and research in order to reveal the significance of her variant gene and its 
correlation with cancer. Complaint, supra note 59, at 11. 
 109. Complaint, supra note 59, at 11. 
 110. Merz & Cho, supra note 56, at 204. 
 111. Id. at 205. 
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proteins or other therapeutic products associated with the gene.
112
 
The following claims in Patent 5,747,282 (‘282) are illustrative 
of the composition of matter claims at issue: 
1. An isolated DNA coding for a BRCA1 polypeptide, said 
polypeptide having the amino acid sequence set forth in SEQ 
ID NO: 2. 
2. The isolated DNA of claim 1, wherein said DNA has the 
nucleotide sequence set forth in SEQ ID NO:1 . . . 
5. An isolated DNA having at least 15 nucleotides of the DNA 
of claim 1. 
6. An isolated DNA having at least 15 nucleotides of the DNA 
of claim 2.
113
 
 
There are three types of isolated DNA molecules claimed: (1) 
isolated sequences identical to naturally occurring genetic sequences 
which encompass both the full length gene sequence (Claim 1, ‘282); 
(2) shorter isolated DNA strains with as few as fifteen nucleotides 
found on the chromosome (Claim 5, ‘282); and (3) cDNA molecules 
which differ from the natural gene sequence because the non-coding 
sequences are removed and the nucleotide sequence is the 
complementary sequence of the naturally occurring RNA (equivalent 
to mRNA) (Claim 2, ‘282).114 
B. Diagnostic Method Clams 
Diagnostic gene patents characterize an individual’s genetic 
makeup at a disease-associated location of the individual’s DNA, and 
these types of patents cover all known methods of testing for genetic 
differences.
115
 A single gene may have multiple patent applications 
claiming different diagnostics of mutations or differences in the 
                                                                                                                            
 112. Id. at 206. 
 113. U.S. Patent No. 5,747,282 (filed June 7, 1995). 
 114. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1364 (Fed. Cir. 2011) (Moore, J., concurring). 
 115. Merz & Cho, supra note 56, at 204. 
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sequence.
116
 Some diseases are caused by mutations in multiple 
genes, therefore creating issues if different companies hold patents on 
different diagnostic genetic sequences.
117
 Additionally, patents can 
issue on the same type of diagnostic genetic test, if the same mutation 
is responsible for different types of genetic disorders.
118
 These types 
of diagnostic disease patents can monopolize a diagnostic test, since 
the patents typically claim all methods of testing for a specific 
gene.
119
 
Claim 1 in Patent 5,709,999 (‘999), which looks for mutations in 
natural human genes, is illustrative of the diagnostic claims at issue: 
1. A method for detecting a germline alteration in a BRCA1 gene, 
said alteration selected from the group consisting of the alterations 
set forth in Tables 12A, 14, 18 or 19 in a human which comprises 
analyzing a sequence of a BRCA1 gene or BRCA1 RNA from a 
human sample or analyzing a sequence of BRCA1 cDNA made 
from mRNA from said human sample with the proviso that said 
germline alteration is not a deletion of 4 nucleotides corresponding 
to base numbers 4184-4187 of SEQ ID NO:l.
120
 
C. Functional Use Method Claims 
Claims to the functional use of a gene are based on the discovery 
of the role genes play in a certain disease or cellular function.
121
 
Claim 20 in Patent ‘282 is the sole functional use claim at issue: 
20. A method for screening potential cancer therapeutics which 
comprises: growing a transformed eukaryotic host cell containing 
an altered BRCA1 gene causing cancer in the presence of a 
compound suspected of being a cancer therapeutic, growing said 
transformed eukaryotic host cell in the absence of said compound, 
determining the rate of growth of said host cell in the presence of 
said compound and the rate of growth of said host cell in the 
absence of said compound and comparing the growth rate of said 
host cells, wherein a slower rate of growth of said host cell in the 
presence of said compound is indicative of a cancer therapeutic.
122
 
                                                                                                                            
 116. Id. 
 117. Id. at 204-205. 
 118. Id. at 205. 
 119. Id. at 204. 
 120. U.S. Patent No. 5,709, 999 (filed Nov. 21, 1991). 
 121. See Merz & Cho, supra note 56, at 206. 
 122. U.S. Patent No. 5,747,282 (filed June 7, 1995). 
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V. JUDGE SWEET’S RULING IN THE S.D.N.Y. 
The Association for Molecular Pathology moved for summary 
judgment to declare fifteen claims out of seven different patents 
issued to Myriad Genetics invalid.
123
 In Association for Molecular 
Pathology, molecular biotechnology and patent law collided, 
presenting the question of whether or not isolated human genomic 
sequences and their complementary sequences were patentable.
124
 The 
ruling shocked the patent community, because Judge Sweet ruled 
against the thousands of patents on genes that the USPTO had issued 
over three decades, invalidating both compositions of matter and 
method claims as patent ineligible products of nature under 35 U.S.C. 
§101.
125
 
In concluding that “DNA represents the physical embodiment of 
biological information,” Judge Sweet’s decision emphasized the 
similarity between isolated genes and native DNA as a carrier of 
information.
126
 As carriers of information, DNA has unique 
characteristics from chemical compounds.
127
 Chemical compounds 
only transmit the information that relates to their own production, 
while DNA transmits not only its chemical information, but the 
genetics that form a unique human being.
128
 Based on this reasoning, 
genes were held to be products of nature differentiable from other 
chemical compounds and therefore unpatentable.
129
 
Judge Sweet invalidated the diagnostic method claims because 
they did not specify any other action beyond “analyzing” or 
“comparing” two gene sequences to determine if differences 
existed.
130
 Judge Sweet characterized this comparison or analysis of 
two different sequences as an unpatentable mental process.
131
 Judge 
Sweet also invalidated the singular functional method claim because 
                                                                                                                            
 123. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 
181, 184 (S.D.N.Y. 2010). 
 124. Id. at 185, 198-99. 
 125. See id. at 238. 
 126. Id. at 228. 
 127. Id. 
 128. Id. 
 129. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 
181, 228-29 (S.D.N.Y. 2010). 
 130. Id. at 233-37. 
 131. Id. at 234. 
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it improperly attempted to patent a basic scientific principle.
132
 
VI. COURT OF APPEALS DECISION 
On July 29, 2011, the Federal Circuit issued its ruling, with all 
three judges writing separately.
133
 
A. Standing 
Although the district court found broad standing among all the 
plaintiffs, the Federal Circuit spent significant time in finding that 
only one plaintiff, Dr. Ostrer, had the necessary standing to maintain 
declaratory judgment in the suit.
134
 Dr. Ostrer had standing based on 
the totality of the circumstances: he received a letter from Myriad 
proposing a collaborative license requiring N.Y.U. to make payments 
to Myriad for each non-research test performed; he was aware that 
Myriad was asserting its patent rights against similarly situated 
parties; and as a result of litigation he was forced to send all patient 
samples to Myriad.
135
 In addition, Dr. Ostrer maintained he could 
have proceeded with testing without taking a license due to his belief 
that the patents are invalid, he intended to undertake BRCA1 testing, 
and stated unequivocally that he would immediately begin such 
testing if the patents were ruled invalid.
136
 Furthermore, “Myriad’s 
challenged composition and method claims undisputedly provide[d] 
‘an absolute barrier’ to Dr. Ostrer’s ability to undertake BRCA 
diagnostic testing activities, and a declaration of those claims’ 
invalidity would remove that barrier.”137 The other plaintiffs—
patients, advocacy groups, national organizations, and medical 
organizations—failed to articulate an adverse legal controversy.138 
Judge Lourie held that “[s]imply disagreeing with the existence of a 
patent or even suffering an attenuated, non-proximate, effect from the 
existence of a patent” is not enough to establish standing for 
                                                                                                                            
 132. Id. at 237 (“The recited transformative steps . . . represent nothing more than 
preparatory, data-gathering steps to obtain growth rate information and not render the claimed 
mental process patentable under §101.”). 
 133. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1333 (Fed. Cir. 2011). 
 134. Id. at 1344. 
 135. Id. at 1345. 
 136. Id. at 1345-46. 
 137. Id. at 1348. 
 138. Id. 
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declaratory judgment.
139
 
B. Method Claims 
The district court’s decision predated Bilski’s rejection of the 
machine-or-transformation test as the exclusive test for determining a 
patent eligible process.
140
 In light of Bilski, Judge Lourie determined 
all the diagnostic method claims were directed to patent-ineligible 
abstract mental processes and therefore fail the machine-or-
transformation test.
141
 
Myriad’s diagnostic method claims that “compare” or “analyze” 
two gene sequences fell outside the scope of §101.
142
 The claims 
recite “nothing more than the abstract mental steps necessary to 
compare two different nucleotide sequences.”143 Myriad’s claims did 
not include a step where the BRCA gene sequence must first be 
“determined.”144 In contrast, Myriad’s method claims to potential 
cancer therapeutics were determined to be a patent-eligible process 
because they included the step of “determining” the cells’ growth 
rates, which necessarily involves physical manipulation of the cells 
and are central to the purpose of the claim.
145
 
C. Composition of Matter Claims: Isolated DNA Molecules 
Judge Lourie summarized the debate over the patentability of 
isolated DNA molecules as a disagreement “on whether and to what 
degree such molecules fall within the exception for products of 
nature.”146 The disagreement on whether and what degree such 
molecules qualify as an exception to patentable subject matter 
permeated all three different Federal Circuit judicial opinions as 
well.
147
 
                                                                                                                            
 139. Id. 
 140. Id. at 1355. 
 141. Id. 
 142. Id. 
 143. Id. at 1356. 
 144. Id. at 1357. 
 145. Id. 
 146. Id. at 1350. 
 147. See generally id. 
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1. Majority Opinion, Judge Lourie  
Judge Lourie, in applying the Chakrabarty-Funk Brothers 
“markedly different” framework, held that isolated DNA molecules 
are markedly different due to their distinctive chemical identity and 
nature from molecules that exist in nature.
148
 Judge Lourie stressed 
that chemical covalent bonds must be broken in order to form an 
isolated DNA segment and that isolated DNA segments can be 
independently synthesized.
149
 Judge Lourie distinguished isolated 
DNA molecules from purification, describing purification as a 
process resulting in an identical molecule in pure form.
150
 Judge 
Lourie suggested DNA is not purified in its isolated form, because 
isolated genetic sequences do not exist within a physical mixture from 
which it can be purified—they must be chemically cleaved from their 
chemical composition with other genetic material.
151
 
Judge Lourie also indicated that Judge Sweet wrongly 
determined patentability based on DNA’s genetic function—
transformation of information—rather than what it is: a distinct 
chemical entity.
152
 The majority opinion emphasized deference to the 
legislature and long-standing USPTO practice.
153
 Judge Lourie noted 
that the Supreme Court has “more than once cautioned that courts 
‘should not read into the patent laws limitations and conditions which 
                                                                                                                            
 148. Id. at 1351. 
Native DNA exits in the body as one of forty-six large, contiguous DNA 
molecules. Each DNA molecule is itself an integral part of a larger structural 
complex, a chromosome. In each chromosome the DNA molecule is packaged 
around histone proteins into a structure called chromatin, which in turn is 
packaged into the chromosomal structure. Isolated DNA, in contrast, is a free 
standing portion of a native DNA molecule, frequently a single gene. Isolated 
DNA has been cleaved (i.e., had covalent bonds in its backbone chemically 
severed) or synthesized to consist of just a fraction of a naturally occurring DNA 
molecule. 
Id. 
 149. Id. at 1352-1353. 
 150. Id. at 1352. 
 151. Id. 
 152. Id. at 1353 (“Uses of chemical substances may be relevant to the non-obviousness of 
these substances or to method claims embodying those uses but the patent eligibility of an 
isolated DNA is not negated because it has similar informational properties to a different more 
complex natural material that embodies it.”). 
 153. Id. at 1354-55 (Because of the thousands of genetic patents and longstanding USPTO 
practice of granting these type of patents, Judge Lourie noted that a categorical exclusion to 
patentable subject matter should come from Congress and not the Judiciary). 
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the legislature has not expressed.’”154 
2. Concurring Opinion, Judge Moore  
 In his concurring opinion, Judge Moore emphasized that he did 
not believe that the different chemical structure emphasized by Judge 
Lourie rendered the isolated DNA per se patentable.
155
 Judge Moore 
also suggested that an isolated genetic sequence is not per se 
unpatentable as a law of nature, as Judge Sweet held, given the 
chemical differences highlighted by Judge Lourie.
156
 Judge Moore 
framed the issue as whether the chemical differences in the isolated 
genetic sequences impart a new utility, which makes the molecule 
markedly different than they occur in nature.
157
 
Judge Moore easily found claims to shorter isolated genetic 
molecules patentable, because they can be used as primers in 
diagnostic screening processes to detect gene mutations, or as probes 
with isolated radiolabeled sequences mirroring those on the 
chromosome.
158
 In contrast, naturally occurring DNA cannot be used 
to accomplish either of these two functions.
159
 Judge Moore found 
longer strands of isolated DNA presented a “closer case” than shorter 
isolated DNA strands.
160
 A fully sequenced isolated gene maintains 
the same chemical differences as a shorter strand of isolated DNA; 
however, it is too long to be used as a probe and is unsuitable as a 
primer; therefore, larger strands of isolated DNA do not enlarge the 
range of utility.
161
 Judge Moore found that the settled expectations of 
                                                                                                                            
 154. Id. at 1353. 
 155. Id. at 1364-65 (Moore, J., concurring in part). 
 156. Id. at 1365. 
 157. Id. 
 158. See id. 
The ability to use isolated DNA molecules as the basis for diagnostic genetic 
testing is clearly an “enlargement of the range of . . . utility” as compared to 
nature. . . . Because the different chemical structure of the isolated DNA, which 
is a product of the intervention of man, leads to a different and beneficial utility, I 
believe small, isolated DNA fragments are patentable subject matter. . . . Man has 
whittled the chromosomal DNA molecule down to a 15 nucleotide sequence—
defining the parts to be retained and discarded. And the result is a product with a 
function (primer or probe) that is entirely different from the full gene from which 
it was obtained. 
Id. 
 159. Id. 
 160. Id. at 1366. 
 161. See id. 
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patent law “tip the scale in favor of patentability.”162 
3. Dissenting Opinion, Judge Bryson 
 Judge Bryson held that isolated genetic sequences are 
categorically unpatentable as composition of matter claims.
163
 Judge 
Bryson framed the issue as whether an inventor could obtain a patent 
on a human gene.
164
 The dissent compared the isolated genetic 
sequences to minerals that are hard to extract from a natural setting, 
and compared the cleaving of a covalent bond to the cleaning of a 
diamond with water or solvent to remove dirt or grime.
165
 Judge 
Bryson’s reasoning was similar to Judge Sweet’s reasoning in the 
district court opinion. Judge Bryson based his holding on the belief 
that the structural differences are irrelevant because the function of 
the genetic sequence is the same as the native DNA—both transfer 
information, whether it is being used in the body to code a protein or 
used as a primer or a probe in diagnostic technologies.
166
 
Judge Bryson characterized the majority opinion’s deference to 
past precedent as adverse possession in patent law.
167
 To counter the 
majority’s reliance on USPTO precedent and deference to the 
legislature, Judge Bryson further justified his stance based on the 
following: the ruling in Chakrabarty that rendered microorganisms 
patentable in the face of USPTO policy that microorganisms were not 
patentable, the USPTO’s lack of rule-making authority, and the 
Department of Justice’s Opinion on behalf of the United States.168 
Judge Bryson additionally cited policy arguments relating to the 
preemptive force of these patents resulting in a biotechnology 
“anticommons” as a reason against patentability.169 
                                                                                                                            
 162. Id. at 1367. 
 163. See id. at 1373-74 (Bryson, J., concurring in part and dissenting in part). 
 164. Id. at 1373. 
 165. See id. at 1375. 
 166. See id. at 1378 (The identity is key to its value. If it were altered in any meaningful 
way it could not be used for its diagnostic value). 
 167. See id. at 1381. 
 168. Id. at 1380-81. 
 169. See id. at 1379-80. 
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VII.WHAT NOW? LOOKING PAST THE COURT OF APPEALS DECISION 
Both parties petitioned the Federal Circuit for rehearing.
170
 The 
Association for Molecular Pathology moved for rehearing based on 
the claims to the isolated genetic sequences and an error in the 
determination of standing.
171
 Myriad’s petition for rehearing focused 
only on standing and urged the Federal Circuit to dismiss the case as 
moot based on Dr. Ostrer’s departure from N.Y.U.172 Interestingly, 
while Myriad asked to dismiss the case as moot, they did not ask to 
vacate the judgment,
173
 likely because the judgment was mostly 
favorable to them in the assurance of the validity of genetic 
sequences. Additionally, Myriad did not ask for a rehearing on the 
diagnostic claims.
174
 However, the Federal Circuit denied both 
petitions for rehearing.
175
 While the plaintiffs have filed a petition for 
review in front of the Supreme Court,
176
 even if review is granted, the 
outcome is uncertain for the following reasons. 
A. Standing 
By the time this case reaches a Supreme Court appeal, the parties 
may no longer have standing. Dr. Ostrer has left N.Y.U. and is 
currently at the Department of Genetics at Albert Einstein College of 
Medicine,
177
 which does not have the ability to perform clinical 
genetic testing.
178
 The requirement to maintain standing continues 
throughout the appellate process.
179
 Dr. Ostrer no longer has the 
                                                                                                                            
 170. See generally Plaintiffs-Appellees’ Petition for Panel Rehearing, supra note 9; 
Defendants-Appellants’ Petition for Panel Rehearing, supra note 9. 
 171. See Plaintiffs-Appellees’ Petition for Panel Rehearing, supra note 9, at 1, 11. 
 172. See Defendants-Appellants’ Petition for Panel Rehearing, supra note 9, at 1. 
 173. See id. at 9-11. 
 174. See generally id. 
 175. See Disposition Sheet, U.S. CT. OF APPEALS FOR THE FED. CIR. (Sept. 12, 2011), 
http://www.cafc.uscourts.gov/images/stories/disposition/daily.pdf (last visited Sept. 17, 2011). 
 176. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1367 (Fed. Cir. 2011), petition for cert filed, (U.S. Dec. 07, 2011) (No. 11-725). 
 177. See Faculty Profile for Harry Ostrer, M.D., ALBERT EINSTEIN C. OF MED., 
http://www.einstein.yu.edu/home/faculty/profile.asp?id=12751&k (last visited Feb. 29, 2012). 
 178. Letter from Gregory A. Castanias, Attorney for Defendants-Appellants, to Mr. Jan 
Horbaly, Clerk at the U.S. Ct. of Appeals for the Fed. Cir. 1 (July 27, 2011), available at 
http://inventivestep.files.wordpress.com/2011/07/myriadletter1.pdf [hereinafter Castanias 
Letter]. 
 179. See Lewis v. Cont’l Bank Corp., 494 U.S. 472, 477-78 (1990). 
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ability to immediately resume testing, which would likely extinguish 
his standing.
180
 
It is unlikely that the Supreme Court would apply the district 
court’s broad finding of standing to the other plaintiffs. Judge Sweet’s 
sweeping finding of standing was a dangerous test that does not align 
with patent law. Judge Lourie was correct in his reasoning that 
“[s]imply disagreeing with the existence of a patent or even suffering 
an attenuated, non-proximate, effect from the existence of a patent 
does not meet the Supreme Court’s requirement for an adverse legal 
controversy or sufficient immediacy and reality to warrant the 
issuance of a declaratory judgment.”181 Allowing a broad base of 
people, in this case patients, to litigate the validity of patents would 
open the floodgates of litigation. Ex parte re-examinations already 
allow third parties to question the validity of patents. Patent holders 
are granted a twenty-year monopoly for their investment and 
disclosure of their technology to the public knowledge base. A 
twenty-year monopoly will inevitably harm consumers of the product 
in some general way, but giving them standing does not create a 
remedy for the injury. It only serves to weaken the patent system. 
B. Composition of Matter Claims 
As evidenced by the separately written judicial opinions, the 
divide between both scientific and legal minds in dozens of amicus 
briefs,
182
 and disagreement even within the branches of 
                                                                                                                            
 180. See Castanias Letter, supra note 177, at 2. 
 181. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1348 (Fed. Cir. 2011). 
 182. Compare, e.g., Brief for AARP as Amicus Curiae in Support of Plaintiffs-Appellees 
and Arguing for Affirmance at 2-4, Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 585711 (arguing that DNA 
and human genes are unpatentable under 35 U.S.C. §101 and the patents should be declared 
unenforceable, because public health necessitates their invalidation); Brief for the S. Baptist 
Convention as Amicus Curiae in Support of Plaintiffs-Appellees and Arguing for Affirmance at 
2, Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 
2011) (No. 2010-1406), 2011 WL 585712 (arguing that gene sequence patents are unpatentable 
subject matter and are harmful to individuals no matter what their religious beliefs); Brief of 
Amici Curiae E. Richard Gold et al. in Support of Appellees and Affirmance at 26, Ass’n for 
Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (No. 
2010-1406), 2010 WL 5558511 (arguing that the genetic sequence contained in DNA should be 
considered as information, and should therefore be excluded as unpatentable abstract subject 
matter unless the claim has a specific function), with, e.g., Brief of Amici Curiae Rosetta 
Genomics, Ltd. et al. in Support of Defendants-Appellants, Supporting Reversal at 14-28, Ass’n 
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government,
183
 reasonable people differ on how science and patent 
law should align. Opinions on the patentability of genes vary not so 
much because of the legal analysis, but because of the strong 
emotions behind the issue. While both the majority and concurring 
opinions in the Federal Circuit found that public policy fell on the 
side of deference to long-held property rights, Judge Bryson’s 
dissenting opinion emphasized that his view of public policy 
outweighed that deference.
184
 Therefore, the view on how patent law 
should be applied to science is inextricably intertwined with policy. 
In Chakrabarty, the Supreme Court faced a similarly divisive 
issue.
185
 Chakrabarty, like Myriad, presented the judiciary with a 
“gruesome parade of horribles” in several amicus briefs in support of 
the plaintiff’s argument against the patentability of genetic 
                                                                                                                            
for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) 
(No. 2010-1406), 2010 WL 4853324 (arguing that isolated DNA is patentable subject matter, 
and patents stimulate innovation). 
 183. See, e.g., Brief for the U.S. as Amicus Curiae in Support of Neither Party at 9-11, 
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 
2011) (No. 2010-1406), 2010 WL 4853320; Heidi Ledford, Has the US Government Abandoned 
Gene Patents?, NATURE.COM NEWSBLOG (Nov. 1, 2010), 
http://blogs.nature.com/news/2010/11/will_the_us_government_abandon.html (“[N]o lawyers 
from the patent office are listed on the brief – a possible sign that the position has few fans at the 
USPTO, which has granted thousands of gene patents over the years.”); David Kappos, Under 
Sec’y of Commerce for Intellectual Prop., Building Bridges and Making Connections Across the 
IP System, Speech at the George Washington Law Symposium 3 (May 11, 2010), in 
USPTO.GOV, available at 
http://www.uspto.gov/news/speeches/2010/Kappos_GW_Law_Symposium.jsp. 
This has a potentially enormous impact on the bio industry. The USPTO has 
issued more than 20,000 patents claiming isolated DNA molecules, almost 4,000 
of which directly claim isolated human DNAs encoding a protein. The USPTO 
has also issued tens of thousands of patents on other types of isolated and 
purified chemicals, all of which could be put at risk by the District Court’s 
decision. The USPTO has for decades issued patents covering isolated and 
purified DNA on the scientific basis that an isolated snippet of DNA does not 
“exist” in nature in the way it is claimed in patents, because naturally occurring 
DNA must be isolated—that is, separated from the surrounding biological 
material—and purified. Your body does not contain isolated DNA. Isolated DNA 
simply is not found in nature. 
Id. 
 184. Ass’n for Molecular Pathology, 653 F.3d at 1373 (Bryson, J., concurring in part and 
dissenting in part) (“In my view, those claims are not directed to patentable subject matter, and 
if sustained the court’s decision will likely have broad consequences, such as preempting 
methods for whole-genome sequencing, even through Myriad’s contribution to the field is not 
remotely consonant with such effects.”). 
 185. See Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980). 
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inventions.
186
 The court noted that “[t]hese arguments are forcefully, 
even passionately, presented; they remind us that, at times, human 
ingenuity seems unable to control fully the forces it creates—that, 
with Hamlet, it is sometimes better ‘to bear those ills we have than fly 
to others that we know not of.’”187 The Supreme Court strongly 
emphasized that Congress, and not the Court, should decide 
categories of statutory exclusion, especially when based on public 
policy: 
What is more important is that we are without competence to 
entertain these arguments—either to brush them aside as fantasies 
generated by fear of the unknown, or to act on them. The choice 
we are urged to make is a matter of high policy for resolution 
within the legislative process after the kind of investigation, 
examination, and study that legislative bodies can provide and 
courts cannot. That process involves the balancing of competing 
values and interests, which in our democratic system is the 
business of elected representatives. Whatever their validity, the 
contentions now pressed on us should be addressed to the political 
branches of the Government, the Congress and the Executive, and 
not to the courts.
188
 
Chakrabarty is dispositive. If a categorical statutory exclusion to 
genetic patents is created, dislodging long-held property rights, the 
decision should be made by Congress and not the judiciary. 
“Congress is free to amend §101 so as to exclude from patent 
protection” genetic sequences under the product of nature exception, 
“[o]r it may choose to craft a statute specifically designed” to address 
them.
189
 Until Congress takes such actions, the Court must strictly 
construe the language of §101 as it currently exists.
190
 
In his dissent, Judge Bryson used Chakrabarty as an affirmation 
that the Supreme Court does not owe deference to past patent law 
policy, because the Court created a new category of patent protection 
in microorganisms.
191
 However, interpreting a statute as granting a 
                                                                                                                            
 186. Id. at 316. 
 187. Id. 
 188. Id. at 317. 
 189. Id. at 318. 
 190. Id. at 318 (“Our task, rather, is the narrow one of determining what Congress meant 
by the words it used in the statute; once that is done our powers are exhausted.”). 
 191. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1381 (Fed. Cir. 2011) (Bryson, J., concurring in part and dissenting in part) (“Finally, prior to 
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property right where none existed before is much different than taking 
away a property right that has existed for thirty years resulting in the 
grant of thousands of patents without significant congressional action. 
Traditionally, Congress does not need to authorize the patentability of 
new fields of inventions, since breakthrough innovations often stretch 
beyond the boundaries of science.
192
 In contrast, an invention that has 
been around for decades provides Congress with ample opportunity to 
create legislation if they do not wish that type of invention to be a part 
of the patent bargain. Congress does not need to explicitly authorize 
inventions, but once an invention has been deemed patent eligible and 
Congress has not acted to prevent the issuance of thousands of patents 
over several decades, the judiciary should not arbitrarily overturn the 
long-standing property right. 
Judge Bryson incorrectly suggested that the executive’s 
Department of Justice brief in support of neither party indicated that 
the patent office has changed their stance on genetic sequence 
patents.
193
 On May 11, 2010, the director of the USPTO, David 
Kappos, said in a speech to the George Washington Law Symposium: 
The USPTO has for decades issued patents covering isolated and 
purified DNA on the scientific basis that an isolated snippet of 
DNA does not “exist” in nature in the way it is claimed in patents, 
because naturally occurring DNA must be isolated—that is, 
separated from the surrounding biological material—and purified. 
Your body does not contain isolated DNA. Isolated DNA simply is 
not found in nature. . . . It has been the view of the USPTO that the 
purified version of a naturally occurring compound—where the 
purified version does not exist in nature—is eligible for patent 
protection.
194
 
On November 1, 2010, David Kappos reaffirmed that view point 
even in light of the Department of Justice’s brief, and told the DOW 
Jones news service: “The USPTO at the present time is maintaining 
                                                                                                                            
the Supreme Court’s decision in Chakrabarty, the PTO had determined that microorganisms 
were not subject to patenting, but the Supreme Court gave no indication that it regarded that 
view as entitled to deference.”). 
 192. See Chakrabarty, 447 U.S. at 316 (“A rule that unanticipated inventions are without 
protection would conflict with the core concept of the patent law that anticipation undermines 
patentability. . . . Congress employed broad general language in drafting § 101 precisely because 
such inventions are often unforeseeable.”). 
 193. See Ass’n for Molecular Pathology, 653 F.3d at 1380-81 (Bryson, J., concurring in 
part and dissenting in part). 
 194. Kappos, supra note 182, at 3-4. 
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the status quo. We’re continuing with current procedures as they 
are.”195 Clearly, the Department of Justice’s brief did little to dictate 
USPTO policy on genetic sequences. 
Accordingly, the Supreme Court should interpret 35 U.S.C. §101 
through strict interpretation, apply it to the science, and rightly defer 
the public policy arguments to Congress. It is unlikely that the 
Supreme Court would declare all patents to genetic sequences as 
categorically unpatentable as a product of nature. It is incorrect to 
focus solely on the similarity between isolated DNA and native DNA 
as an informational carrier, rather than the differences. Chakrabarty 
clearly states that the applicable test does not focus on the similarities, 
but whether the non-naturally occurring composition of matter was a 
product of human ingenuity with “distinctive name, character [and] 
use.”196 The compositions of matter claims in fact do not claim the 
raw information of the genetic sequence of BRCA1 and BRCA2.
197
 
The claim is an isolated man-made DNA molecule with an amino 
acid sequence that carries the raw information of the genetic 
sequence. It is the molecule that is claimed, not the information. In 
other words, the molecule would not exist but for man’s intervention. 
Under a strict interpretation of §101, a composition of matter 
claim to an isolated genetic sequence is patent eligible because it is a 
product of human ingenuity, non-naturally occurring, and has a 
distinctive character, name and use. In this case, the claimed sequence 
could be used as primer and probe in the detection of genetic 
abnormalities, and native DNA could not. “Isolated DNA” does not 
exist in nature, and isolation often tips the scales to patentability.
198
 
Although larger sequences of isolated genetic sequences may not 
have the practicality of primer or probe, policy weighs in their favor 
as Judge Moore outlined in her concurring opinion,
199
 and they are 
still man-made molecules with a distinct chemical composition that 
                                                                                                                            
 195. Gene Quinn, Conflicting Positions on Gene Patents in Obama Administration, IP 
WATCHDOG (Nov. 2, 2010, 2:27 PM), http://ipwatchdog.com/2010/11/02/conflicting-positions-
on-gene-patents-in-obama-administration/id=13085/. 
 196. Chakrabarty, 447 U.S. at 309-10 (alteration in original) (quoting Hartranft v. 
Wiegmann, 121 U.S. 609, 615 (1887)). 
 197. See generally U.S. Patent No. 5,747,282 (filed June 7, 1995). 
 198. See Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911),  
aff’d in part, rev’d in part, 196 F. 496 (2d Cir. 1912). 
 199. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 
1329, 1366-67 (Fed. Cir. 2011) (Moore, J., concurring in part). 
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do not occur in nature.
200
 The Supreme Court should not overturn 
decades of recognized property rights through a categorical exclusion 
of genetic sequences as “products of nature”—the Court will rightly 
defer the policy arguments to Congress. 
C. The Diagnostic Method Claims 
Less than a year prior to the Myriad decision, Judge Lourie ruled 
on a similar diagnostic method claim in Prometheus.
201
 The following 
method claim was representative of the claims at issue in Prometheus: 
1. A method of optimizing therapeutic efficacy for treatment of 
an immune-mediated gastrointestinal disorder, comprising: 
(a) administering a drug providing 6–thioguanine to a 
subject having said immune-mediated gastrointestinal 
disorder; and 
(b) determining the level of 6–thioguanine in said subject 
having said immune-mediated gastrointestinal disorder, 
wherein the level of 6–thioguanine less than about 230 pmol 
per 8x10
8
 red blood cells indicates a need to increase 
the amount of said drug subsequently administered to 
said subject and 
wherein the level of 6–thioguanine greater than about 400 
pmol per 8x10
8
 red blood cells indicates a need to 
decrease the amount of said drug subsequently 
administered to said subject.
202
 
This claim essentially covers administration of a drug, a 
determination of a corresponding natural correlation in the human 
body based on that drug, and the result of that determination being 
compared to a predetermined amount. Judge Lourie held that the 
                                                                                                                            
 200. See Ass’n for Molecular Pathology, 653 F.3d at 1351-52; Kappos, supra note 182, at 
4 (“It has been the view of the USPTO that the purified version of a naturally occurring 
compound—where the purified version does not exist in nature—is eligible for patent 
protection.”). 
 201. See Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 1349 (Fed. 
Cir. 2010), cert. granted, 131 S. Ct. 3027 (June 20, 2011). 
 202. Id. at 1350. 
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administering and determining steps were both transformative and 
central to the claims; therefore, Judge Lourie held the claim to be 
valid.
203
 
When Myriad is read in correspondence with Prometheus, the 
differentiation between method claims written without a 
“determining” step and claims written with a “determining” step is 
slim.
204
 Myriad argued that steps of extracting a human DNA sample 
and sequencing the BRCA molecule from that human DNA sample 
necessarily preceded the comparing step, and should be read into the 
claim.
205
 However, Judge Lourie interpreted the claims as only 
comparison between two sequences “accomplished by mere 
inspection alone.”206 If the diagnostic method claims in Myriad had a 
step in which the determining of the genetic sequence was obtained 
through the use of an isolated genetic sequence, Judge Lourie likely 
would have upheld these claims as patent eligible based on his 
holding in Prometheus. Judge Lourie’s distinction between the 
method claims in Prometheus and the method claims in Myriad is 
mere semantics. If this narrow distinction is upheld, it will do little 
more than alter the way in which diagnostic method claims are 
drafted. 
The Supreme Court appears to be positioning itself for a ruling 
on biomedical method claims in the near future. In 2006, the Supreme 
Court granted, and then dismissed as “improvidently granted,” review 
to Labcorp v. Metabolite.
207
 With no majority opinion, Justice Breyer, 
joined by Justice Stevens and Justice Souter, wrote a dissenting 
opinion.
208
 The claims, which were determined to be valid in the 
                                                                                                                            
 203. Id. at 1357, 1359. 
 204. See, e.g., U.S. Patent No. 5,709,999 col. 161 17-25 (filed Nov. 21, 1991).  
Claim 1: 
A method for detecting a germline alteration in a BRCA1 gene, said alteration 
selected from the group consisting of the alterations set forth in Tables 12A, 14, 
18 or 19 in a human which comprises analyzing a sequence of a BRCA1 gene or 
BRCA1 RNA from a human sample or analyzing a sequence of BRCA1 cDNA 
made from mRNA from said human sample with the proviso that said germline 
alteration is not a deletion of 4 nucleotides corresponding to base numbers 4184-
4187 of SEQ ID NO:l. 
Id. 
 205. See Ass’n for Molecular Pathology, 653 F.3d at 1356. 
 206. Id. at 1357. 
 207. Labcorp v. Metabolite Labs., Inc., 548 U.S. 124, 125 (2006) (per curiam). 
 208. Id. 
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lower courts, were directed to a process of measuring the level of an 
amino acid and human body fluid and noticing whether the level was 
elevated above the normal level in order to detect vitamin 
deficiency.
209
 Justice Breyer argued that a correlation between 
homocysteine and vitamin deficiency was a correlation that falls 
under the “natural phenomenon” exception to section 101 
patentability, which cannot be avoided by an instruction to perform 
the process of reading numbers in light of medical knowledge.
210
 
The Supreme Court has granted review of Prometheus and will 
likely issue a ruling this fall.
211
 Based on the Supreme Court’s grant 
of review in Prometheus, Justice Breyer’s dissent in Labcorp v. 
Metabolite, and the Court of Appeals holding in Association for 
Molecular Pathology, diagnostic method claims comparing a “natural 
correlation” are at the forefront of the biotechnology battle. The 
Supreme Court’s future ruling in Prometheus may dictate how the 
Court will proceed in biotechnology cases, and will determine how 
the Court will proceed in Association for Molecular Pathology at least 
in regards to the method claims at issue. 
Prometheus, Labcorp, and Association for Molecular Pathology 
highlight why patent law in biotechnology should not be bulldozed in 
order to attempt to address patient needs that are tangentially affected 
through patent law. All of these cases touch on diagnostic 
technologies. Of these three cases, only Myriad’s claims related to 
genetic diagnostics. Therefore, even if Myriad’s patents were struck 
down, the issues faced by the patients seeking treatment through all 
types of diagnostic technologies would not benefit from their 
invalidation. Notably, the method claims in Myriad were found 
unpatentable not because they were a natural phenomenon, but 
because they were an abstract mental process.
212
 This distinction will 
not create a bar to patenting diagnostic biotechnology tests that use 
natural phenomenon like metabolite correlations, genetic sequences, 
or chemical responses as long as they do not claim only an abstract 
mental process and satisfy Bilski’s “useful and important clue” of the 
                                                                                                                            
 209. Id. 
 210. Id. at 134, 137. 
 211. See Docket for No. 10-1150, SUPREME CT. OF THE UNITED STATES, 
http://www.supremecourt.gov/Search.aspx?FileName=/docketfiles/10-1150.htm (last visited 
Oct. 7, 2011). 
 212. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 
1329, 1355 (Fed. Cir. 2011). 
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machine or transformation test.
213
 
Fundamentally, the issues presented in Myriad circulate around 
better patient care. Therefore, weakening patent protection at best 
provides an ineffective piecemeal approach of targeting limited issues 
in patient service. Biotechnology research is extremely expensive, and 
weakening patents in this sector only serves to disincentivize much 
needed private funding into medical technologies. Invalidation of 
Myriad’s patent would be extremely limited in its scope and effect.214 
This is a broad issue, and should therefore be addressed in a manner 
that would actually address the needs of patients. 
VIII.POLICY CONSIDERATIONS AND POSSIBLE SOLUTIONS 
In April 2010, the Secretary of Health and Human Service’s 
advisory committee on genetics, health, and society (SACGHS) wrote 
a report in conjunction with NIH on Gene Patents and Licensing 
Practices and Their Impact on Patient Access to Genetic Tests.
215
 
Because it was unclear how a congressional ban on genetic sequences 
would affect other biotechnologies including therapeutic uses of 
genes, SACGHS concluded that it was prudent to narrowly tailor any 
solution “to improve genetic test development and patient access 
without affecting patent rights in other areas.”216 The Committee, 
therefore, did not recommend a congressional ban on genetic 
sequences.
217
 
Recently, Congress and the Executive Branch took a narrow 
approach to patents on genetic sequences. President Obama signed 
into law the America Invents Act on September 16, 2011.
218
 Section 
                                                                                                                            
 213. See Bilski v. Kappos, 130 S.Ct. 3218, 3227 (2010). 
 214. See U.S. DEPT. OF HEALTH & HUMAN SERVS., GENE PATENTS AND LICENSING 
PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS: REPORT OF THE 
SECRETARY’S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY 92 (2010) 
[hereinafter SACGHS REPORT] , available at 
http://oba.od.nih.gov/oba/sacghs/reports/SACGHS_patents_report_2010.pdf (“Furthermore, 
even if the plaintiffs prevail, this would not lead to the automatic invalidation of all existing 
patents on genes and associations.”). 
 215. See generally id. 
 216. Id. at 91-92. 
 217. Id. 
 218. Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 27(a), 125 Stat. 283, 338 
(2011) (to be codified in scattered sections of 35 U.S.C.), available at 
http://www.gpo.gov/fdsys/pkg/PLAW-112publ29/pdf/PLAW-112publ29.pdf. See also Press 
Release, The White House, President Obama Signs America Invents Act, Overhauling the 
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27 specifies that the “Director [of the USPTO] shall conduct a study 
on effective ways to provide independent, confirming genetic 
diagnostic test activity where gene patents and exclusive licensing for 
primary genetic diagnostic tests exist.”219 Notably, the study calls for 
research into second opinions on diagnostic tests and nothing more. 
The report is due no later than 9 months after the enactment of the 
Act.
220
 This is an extremely narrow provision in an act with lengthy 
patent reform. If Congress had wanted to create an exception to 
genetic sequence patentability they could have done so while passing 
this act. 
Proponents of invalidating genetic patents cite several policy 
concerns in support of their contention that patent claims to genetic 
sequences “cause more harm than good to society and technological 
development.”221 There are three general categories of concern: 
preemption of future research; quality of care and patient access; and 
an unearned extended patent monopoly. Most of these concerns are 
misplaced, and in fact, would not be well addressed by creating a 
broad exception to section 101 patentability. 
A. Weakening Patent Rights in Biotechnology Would Both 
Negatively Impact Private Investment and Create 
Uncertainty in the Protection of Other Biotechnology 
Property Rights 
Scientific research and development of life-saving technologies 
is expensive and private investment and competition significantly 
contributes to the efficient development of new technologies; 
however, investment in private research will not continue if there is 
no reward. In 2009, BIO (Biotechnology Industry Organization) 
conducted a survey of 150 biotechnology companies.
222
 The survey 
found that half of the companies were founded on the basis of 
                                                                                                                            
Patent System to Stimulate Economic Growth, and Announces New Steps to Help Entrepreneurs 
Create Jobs (Sept. 16, 2011), available at http://www.whitehouse.gov/the-press-
office/2011/09/16/president-obama-signs-america-invents-act-overhauling-patent-system-stim. 
 219. Leahy-Smith America Invents Act § 27(a). 
 220. See Leahy-Smith America Invents Act § 27(d). 
 221. See Mary Mitchell & Dana A. Remus, Commentary, Interstitial Exclusivities After 
Association for Molecular Pathology, 109 MICH. L. REV. FIRST IMPRESSIONS 34, 34-35 (2010), 
available at http://www.michiganlawreview.org/assets/fi/109/mitchellremus.pdf. 
 222. See BIO 2009 Member Survey, BIOTECHNOLOGY INDUSTRY ORGANIZATION, 1 
(2009), http://www3.bio.org/ecs/bd/TechTransfer_Survey_Summary_Conclusions.pdf. 
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obtaining a licensing agreement and that the majority of companies 
with no marketed product expected to spend five to fifteen years 
developing the product.
223
 In the House of Representatives hearing on 
Gene Patents and Other Genomics, Dennis Henner from Genentech, 
Inc., testified that his company invests about $400 million a year in 
the research and development of therapeutic products focusing on the 
identification of human proteins.
224
 
The grant of a patent, in part, recognizes the investment that an 
individual or company assignment has spent in development of a new 
invention. The patent serves as a reward for the investment and risk 
associated with high-priced technologies, especially in the realm of 
biotechnology.
225
 Although the United States government funds most 
basic research (59%), the private business sector accounts for the 
largest share of research and development, hovering between 69-75% 
of total research and development funding.
226
 
Basic research does not bring medical diagnostic technology to 
the market for patient care, and private industry is the largest 
contributor of funds to applied research and development.
227
 
Scientists searching for gene-disease associations cannot perform the 
needed research without significant capital and resources.
228
 Funding 
for meaningful gene-disease associations are confirmed only when the 
basic research discoveries are followed by large amounts of 
replication and validation, which is often cost prohibitive.
229
 The 
research team that founded Myriad received $5 million in funding in 
1993 after the formation of the company.
230
 However, this paled in 
comparison to the $10 million in private stock, along with millions in 
                                                                                                                            
 223. See id. 
 224. Gene Patents and Other Genomic Inventions: Hearing Before the Subcomm. on 
Courts & Intellectual Prop. of the H. Comm. on the Judiciary, 106th Cong. 55 (2000) (statement 
of Dennis J. Henner, Ph.D., Senior Vice President, Research, Genentech, Inc.). 
 225. See generally Science and Engineering Indicators 2008: Chapter 4. Research and 
Development: National Trends and International Linkages, NAT’L SCI. BD. (2008), 
http://www.nsf.gov/statistics/seind08/pdf/c04.pdf. 
 226. See id. at 4-5. 
 227. See Research and Development: Essential Foundation for U.S. Competitiveness in a 
Global Economy, NAT’L SCI. BD. (2008), http://www.nsf.gov/statistics/nsb0803/start.htm 
(“[i]ndustrial contributions to national R&D now far outpace Federal R&D support . . . .” Most 
industrial contributions support applied R&D and not basic R&D.). 
 228. See SACGHS REPORT, supra note 213, at 23. 
 229. See id. 
 230. See Gold & Carbone, supra note 58, at S41. 
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equity from Eli Lilly, a private pharmaceutical company.
231
 Myriad 
has yet to make a profit on the investment it made into the research 
and development of its product.
232
 
On a profit-based research model, a limited patent monopoly 
provides the incentive to investors to take the risk in biotechnology. 
Investors in biotechnology believe that in order to succeed in their 
investment there must be strong, enforceable patents, and any 
perception that patent reform might weaken that patent protection will 
adversely impact the availability of biotechnology funding.
233
 
Biotechnology companies without a successful product on the market 
must rely substantially on the availability of investment funding to 
survive.
234
 In 2000, when Prime Minister Tony Blair and President 
Bill Clinton issued a “bland” statement urging public access to raw 
DNA sequencing information, many biotech companies lost as much 
as 20% of their value.
235
 
Private investors that are providing the funding for research and 
development look at patents as a protection of their investment.
236
 
Myriad’s research into the genetic sequences associated with breast 
cancer was funded by Eli Lilly “in return for licensing privileges for 
diagnostic kits and therapeutic products for BRCA1.”237 The funding 
was therefore based on an exchange—the promise that Myriad would 
be the first to sequence the breast cancer genes in exchange for 
funding. The patents and licensing abilities associated with the rights 
of patents provide much needed capital for biotechnology companies 
to stay in business. 
Weakening patents in the biotechnology sector risks negatively 
impacting investments that bring products to the market 
expeditiously—not only with respect to genetic sequences, but with 
respect to any technology that affects patient care. Congress should 
therefore craft legislation that addresses patient care without 
threatening the property rights that biotechnology companies rely on 
                                                                                                                            
 231. See id. 
 232. Id. at S42. 
 233. See Christopher M. Holman, Biotechnology’s Prescription for Patent Reform, 5 J. 
MARSHALL REV. INTELL. PROP. L. 318, 327-28 (2006). 
 234. See id. at 327. 
 235. See id. at 328. 
 236. See id. at 327-28. 
 237. Bryn Williams-Jones, History of a Gene Patent: Tracing the Development and 
Application of Commercial BRCA Testing, 10 HEALTH L.J. 123, 129 (2002). 
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in attracting investors. 
B. There Is Little to No Evidence that Patents on Genetic 
Sequences Have Hindered Future Research Through 
Preemption and There Are Several Solutions Which Can 
Address These Concerns Without a Blanket Exception to 
Patentability 
Although geneticists first focused on single gene associations to 
one disease, scientists now realize that a specific gene accounts for 
only a small risk of most diseases.
238
 Diagnostic companies are 
therefore shifting their focus to “multiplex tests” which scan for 
dozens of genes.
239
 The ever-lowering cost of genetic sequencing 
suggests that even whole-genome sequencing for diseases will soon 
be practical at a minimal cost.
240
 SACGHS found that patents on 
specific genetic sequences may hinder development of multiplex 
testing, parallel sequencing, and whole genome sequencing due to the 
large amount of licenses that would need to be gathered in order to 
implement the technology.
241
 Proponents against the patentability of 
genetic sequences believe that this type of technology is negatively 
impacted and in some cases preempted by the gene “patent thicket” of 
many different private owners with unaligned interests.
242
 Negotiating 
licenses to every relevant patent directed at a genetic sequence is 
prohibitively expensive and there is little guarantee that every patent 
holder would provide permission or a reasonable price.
243
 The “patent 
thicket” potentially makes it infeasible to offer a product that 
sequenced the genome or multiple genes due to the large number of 
licenses or royalty fees needed in order to avoid patent 
infringement.
244
 
This fear is misplaced. The oft-quoted statistic that twenty 
percent of the genome is patented is incorrect, and many of the 
patents including Myriad’s would not be enforceable against the 
                                                                                                                            
 238. Sam Kean, The Human Genome (Patent) Project, 331 SCI. 530, 530 (2011). 
 239. Id. 
 240. Id. 
 241. SACGHS REPORT, supra note 213, at 3. 
 242. See Kean, supra note 237. 
 243. See SACGHS REPORT, supra note 213, at 3. 
 244. See Kean, supra note 237, at 530-31. 
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technology and process used to sequence the whole genome.
245
 The 
study where this statistic came from did not distinguish between 
patent claims in which the isolated molecule is the invention and 
claims in which a process is using the isolated molecule.
246
 
Universities and nonprofits are less likely to enforce patents 
aggressively and they own most patents on genes used in diagnostic 
tests.
247
 Additionally, many of the genetic patents expired and others 
have terminated for failure to pay fees.
248
 Finally, the remedy for a 
holder of a single gene in a microarray technology that sequenced 
thousands of genomes would be de minimus.
249
 With all of these 
combined factors, the threat of a “patent thicket” inhibiting whole 
genome sequencing or multiplex technologies is minimal. 
In fact, there is no evidence that a “patent thicket” has stopped 
companies from developing these types of technologies.
250
 For 
example, Affymetrix is a company that should have experienced 
considerable difficulty in the creation of their technology. Affymetrix 
is developing a DNA chip with microarrays that might contain 
thousands of genetic sequences.
251
 Yet, this supposed gene “patent 
thicket” has not hindered Affymetrix’s development.252 Another 
example is Foundation Medicine, which is planning to offer a 
diagnostic test that searches for aberrations in a hundred or more 
genes to determine how to treat cancer.
253
 Originally, Foundation 
Medicine estimated that navigating the “patent thicket” would cost at 
least thirty-five million dollars.
254
 However, after fully analyzing the 
                                                                                                                            
 245. Christopher M. Holman, Will Gene Patents Impede Whole Genome Sequencing?: 
Deconstructing the Myth that 20% of the Human Genome is Patented 1-12 (July 25, 2011), 
available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1894715. 
 246. Id. at 2. 
 247. Kean, supra note 237, at 531. 
 248. Holman, supra note 244, at 13. 
 249. Whether the royalty is based on reasonable royalty, market share or lost profits, the 
amount of damages would likely be so minimal for a holder of one patent that targets one gene 
out of thousands and would not outweigh the large costs associated and years required in order 
to reach a verdict in trial. See SACGHS REPORT, supra note 213, at 53. 
 250. See Christopher M. Holman, Patent Border Wars: Defining the Boundary Between 
Scientific Discoveries and Patentable Inventions, 25 TRENDS IN BIOTECHNOLOGY 539, 540 
(2007). 
 251. Id. 
 252. Id. 
 253. Kean, supra note 237, at 530. 
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patents, the company found plenty of room in which to operate.
255
 
Even if there is a small genetic “patent thicket”, it can be navigated in 
several ways. 
1. Patent Pool 
 A patent pool in which several patents are licensed for one price 
can allow companies to easily navigate through patent thickets.
256
 A 
patent pool gathers patents rights to multiple genetic sequences 
together and provides a single license that bundles all of the rights 
together.
257
 This would allow scientists, laboratories, and companies 
working on multiplex and whole genome technologies to easily gather 
permission from all patent holders, pay one pre-determined price, and 
not fear liability in patent infringement suits. 
However, in technologies where patent pools are usually used, 
the technology is interdependent, and no single patent holder is 
capable of marketing their patent technology independently of 
others.
258
 For example, companies like Myriad can profitably market 
their technology without joining the pool and therefore lack incentive 
to join.
259
 A genetic patent pool may not operate as effectively as in 
other technologies. Companies and scientists holding patent on 
individual genes may have highly individually marketable genes that 
would garner little profit, and therefore would have little incentive to 
enter a patent pool. This would provide the same price no matter how 
important the sequenced gene is.
260
 Some hope that multiple holders 
to genetic sequences linked to the same specific condition will 
recognize that it is crucial that each mutation be tested 
simultaneously, and will therefore agree to enter a patent pool or 
cross-licensing agreement.
261
 
Despite potential difficulties in genetic patent pools, patent-
licensing companies and structures have begun to emerge. For 
                                                                                                                            
 255. Id. at 531. 
 256. SACGHS REPORT, supra note 213, at 55 (quoting Birgit Verbeure et al., Patent Pools 
and Diagnostic Testing, 24 TRENDS IN BIOTECHNOLOGY 115, 117 (2006)) (A patent pool is 
defined as an agreement “between two or more patent owners to license one or more of their 
patents as a package to one another, and to third parties willing to pay the associated royalties.”). 
 257. SACGHS REPORT, supra note 213, at 3. 
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 259. Id. at 56. 
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example, MPEG LA,
262
 the “world leader in alternative one-stop 
patent licenses” in April of 2011, created a genetic “supermarket” 
from which a “one-stop patent license” can be purchased.263 The 
company “announced a market-based initiative for a diagnostic 
genetics patent licensing facility that addresses the market’s need for 
nonexclusive access to patents for diagnostic genetics tests leading to 
personalized medical solutions that save lives and reduce healthcare 
costs.”264 If MPEG LA succeeds, the “patent thicket” in genetic 
patents will be a thing of the past. In another example, one 
biotechnology company posted a formula on their website that 
outlined how much the company is willing to pay for every patented 
gene sequenced from the thousands they sequence for every 
customer.
265
 
2. Patent Donation 
 Patent donation could provide a method for companies to donate 
claims to isolated genetic sequences to the public; without 
congressional interference into their companies or subject matter 
limitations on patent law that might result in negative public 
perception and uncertainty in other types of biotechnology patents. 
Considering that most holders of genetic sequence patents allow basic 
research on the genetic sequence to continue, and liberally license 
genetic diagnostic testing to other facilities, a solution to the 
controversial issue may itself be a controversial solution—patent 
donation. 
The genetic sequence patents could be donated to a non-
practicing entity or non-profit such as the Human Genome Project. 
Alternatively, they could be donated to a “trust” created to hold the 
genetic sequences. The donation of existing patents would generate 
good public perception for the companies, and allow for better testing 
and research. Patent donation would allow the owners of the genetic 
sequences to generate good publicity, as opposed to the bad publicity 
                                                                                                                            
 262. MPEG LA, http://www.mpegla.com/main/default.aspx (last visited Mar. 1, 2012). 
 263. Press Release, MPEG LA Launches Initiative to Make Gene Patents Available for 
Diagnostic Testing, MPEG LA (Apr. 8, 2010),  
http://www.mpegla.com/Lists/MPEG%20LA%20News%20List/Attachments/230/n-10-04-
08.pdf. 
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storm generated by Myriad’s business practices.266 Additionally, 
patent donation could provide the companies a tax break for the 
donation of these patents. Congress could enact legislation providing 
a strong tax incentive to companies willing to donate their patents on 
genetic sequences and other basic research tools to the public. A tax 
break and the good public opinion generated by recognizing the 
public need for access to genetic disease research, testing and 
advancement might encourage companies to donate their genetic 
sequence patents. 
One issue with this method of encouraging companies to donate 
genetic sequences to the public domain is that tax incentives do not 
equal a mandate. A company like Myriad generates revenue by 
holding a 20 year exclusionary property right on a diagnostic test that 
affects a large amount of the national population. A tax incentive 
would not measure up to the potential revenue generated by the 
patent, especially for a company that has invested money in research 
and development, lawyers, patent prosecution, patent maintenance 
fees and possible litigation. 
However, companies fearing increased negative perception and 
possible court decisions negating genetic subject matter as patentable 
may be better served in donating their patents on sequences while 
maintaining their other patents. This allows the companies to quell 
any dissatisfaction with the patenting of biological matter, while still 
maintaining patents on genetic diagnostics (which are speculated to 
be so broad as to not actually need a claim on the sequence itself). 
This will ease any uncertainty that investors have in continued biotech 
research, and it will ease public dissatisfaction and the risk of the 
courts etching out sections of the biotech sector as unpatentable. 
In conclusion, there is little evidence that the genetic “patent 
thicket” exists, and even if there is a small thicket the effect has been 
minimal. Potential solutions include patent pools, cross licensing, or 
donation to the public. Companies have already started to implement 
these services. Clearly, current patents on genetic sequences are not 
significantly preempting research and do not justify a broad ruling 
that all genetic sequences are unpatentable. 
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C. Better Patient Treatment Will Not Be Achieved Through 
Invalidation of Patentable Subject Matter 
Patient access to better quality care permeated the complaint in 
Myriad.
267
 When patents create a sole provider of a genetic test, like 
the Myriad test for BRCA1/BRCA2, patients’ access to that test is 
limited based on price, the companies processing capacity, and health 
insurance coverage. When there is only one provider, patients are 
unable to receive a second opinion from an independent laboratory. 
Quality control of a sole provider’s diagnostic test and improvements 
in the methods is often set back, since no other independent lab is 
available to process the sample and verify the results. Additionally, 
insurance companies may not always deem it necessary for a patient 
to receive the test or may not have an agreement with the company 
providing the test. While these are significant issues, the invalidation 
of a patent would not address these concerns. Invalidation of genetic 
sequence patents would not guarantee that other companies would 
offer the diagnostic test, accept medical insurance, provide a lower 
rate, or provide quality assurance. These issues are not patent law 
issues. Other, more narrowly tailored solutions that actually address 
these concerns are outlined below. 
1. Quality Control Through FDA Regulation 
 The quality and accuracy of diagnostic tests could easily be 
monitored within existing regulatory framework. Several government 
agencies are already involved in the oversight of genetic testing.
268
 
The Center for Medicare and Medicaid Services (CMS) regulates 
laboratory compliance under the Clinical Laboratory Improvement 
Amendment of 1988.
269
 The Federal Trade Commission oversees the 
advertising of diagnostic tests.
270
 The Food and Drug Administration 
currently regulates “diagnostic devices” which are manufactured by 
one company and then sold as a kit to another laboratory for genetic 
testing.
271
 The FDA, however, does not regulate diagnostic tests that 
                                                                                                                            
 267. See generally Complaint, supra note 59. 
 268. See Genetic Testing, NAT’L HUMAN GENOME RESEARCH INST., 
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are both manufactured and performed by the same laboratory—like 
the Myriad test.
272
 The Myriad test for BRCA is currently marketed 
directly to the medical community and the public, without any FDA 
regulation or oversight.
273
 The FDA has held public meetings on 
whether they should oversee these types of tests.
274
 The FDA has 
indicated that they believe that these types of tests should fall under 
their oversight.
275
 Greater FDA oversight will come with greater costs 
in the research and development phase of a product, which only 
strengthens the argument that patent protection is needed in order to 
encourage investment in the industry.
276
 
2. Quality Control Through Broader Experimental Use 
Exception and Limited Liability Rule 
 A broader experimental use exception would also allow quality 
assurance to take place in independent laboratories, without that 
laboratory incurring liability. Many industrialized countries recognize 
a much stronger experimental use exception to patent infringement 
liability than the United States currently allows.
277
 There are several 
strong policy arguments for a broader research exemption. Foremost, 
the words in a patent often fail to fully explain the complete nature of 
a biological invention.
278
 Additional reasons include: determining 
how the patent works; whether it works as taught; how to improve it 
and how to work around it.
279
 A more expansive research exemption 
                                                                                                                            
 272. Id. 
 273. Id. 
 274. See generally FDA/CDRH Public Meeting: Oversight of Laboratory Developed Tests 
(LDTs), Date July 19-20, 2010, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm212830.htm (last 
visited Sept. 22, 2011). 
 275. See Dan Vorhaus, DTC Genetic Testing and the FDA: Is There an End in Sight to the 
Regulatory Uncertainty?, GENOMICS LAW REPORT (June 16, 2011), 
http://www.genomicslawreport.com/index.php/2011/06/16/dtc-genetic-testing-and-the-fda-is-
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http://www.genomeweb.com/node/945450. 
 277. Janice Mueller, No “Dilettante Affair”: Rethinking the Experimental Use Exception 
to Patent Infringement for Biomedical Research Tools, 76 WASH. L. REV. 1, 5 (2001). 
 278. See Merz & Cho, supra note 56, at 203. 
 279. Id. at 207. 
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is especially necessary in basic scientific research, where the success 
of an experiment is largely regarded as reproducibility of results and 
minimization of statistical error. It makes little sense to wait until the 
expiration of a patent term to learn if the research actually works. 
One option is to allow the development of new therapies and 
diagnostics through the non-consensual use of the genetic sequences, 
even if ultimately used for commercial purpose, by enforcing a 
“liability rule.”280 The liability rule would compensate the patent 
owner appropriately through an ex post royalty based on the 
marketplace value of any new products developed through use of the 
tool.
281
 This ex post royalty would allow the owner of a gene 
sequence patent to be rewarded only when a profitable expansion of 
his intellectual property had been discovered, while increasing the 
public’s knowledge and furthering scientific process. It would also 
have the added benefit of developing different types of diagnostic 
tests that potentially could serve to increase precision of the tests that 
are developed, while still returning profits to the owner of the patent 
for their investment in sequencing the gene. Therefore, only 
successfully marketed products would incur liability. 
3. Safe Harbor for Second Opinions 
 In an amendment to the 2011 Patent Reform Act, the House of 
Representatives introduced a “safe harbor for second opinions” 
provision. The proposal created a new section 287(d) under the Patent 
Act to establish a safe harbor for second opinion genetic diagnostic 
testing providers,
282
 much like the safe harbor that already exists at 
section 287(c) for medical practitioner performance of medical 
activities.
283
 Although second opinions were one of the issues that the 
ACLU identified in the patent suit against Myriad, they vehemently 
                                                                                                                            
 280. Mueller, supra note 276, at 9-10. 
 281. Id. at 9-10. 
 282. Amendment to H.R. 1249, H.AMDT.491, 112th Cong. § 27 (June 23, 2011), 
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opposed this amendment.
284
 The ACLU noted that “[t]he proposed 
language would fail to block all patent holder objections to such 
testing, fails to address the many other limitations on scientific 
research arising out of the issuance of such patents, and risks allowing 
gene patent holders to argue that Congress implicitly endorses the 
validity of such patents.”285 Following this letter, the safe harbor 
provision was removed.
286
 While this amendment failed, Congress 
clearly does have the ability to create a second opinion safe harbor 
that could apply to all diagnostic tests, but more importantly would 
provide farther-reaching patient care reform than patent invalidation. 
4. Second Opinions and Increased Access Through 
Congressional Legislation: 
 Instead of throwing thousands of genetic patents into question 
and fundamentally altering the national outlook on patentable subject 
matter, Congress should consider narrower approaches in dealing 
with the issue, such as excluding genetic diagnostic methods from the 
patent protection while not completely excluding patents on genetic 
sequences.
287
 Europe allows the patenting of isolated genes while 
preventing the patenting of the diagnostic process such as comparing 
genes to find mutations.
288
 The European patent statute reads, 
“European patents shall not be granted in respect of . . . methods for 
treatment of the human or animal body by surgery or therapy and 
diagnostic methods practi[c]ed on the human or animal body.”289 
This would allow for the concerns of sick individuals to be addressed 
(the need for second opinions, better diagnostics, lower prices, 
insurance coverage and access) while still rewarding biotechnology 
companies for their investment in research. 
In 2002, Representative Lynn Rivers introduced the Genomic 
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Research and Diagnostic Accessibility Act (GRDAA).
290
 GRDAA did 
not affect the patentability of sequenced genes, but would have 
provided limited exemptions from patent infringement liability for 
certain uses of patented genetic sequences and information in the 
context of basic research and diagnostic testing.
291
 The exemption 
would have been very narrow, and may have had little practical effect 
since pure non-commercial research is very rare, but it would have 
provided an exemption from the remedies of a patent infringement 
suit in the performance of genetic diagnostic testing.
292
 There is some 
precedent for this type of exemption, since a medical practitioner is 
exempted from liability for performing a medical or surgical 
procedure.
293
 If genetic testing is considered to be a medical 
procedure, than the exemption may still apply, but the person 
providing the kit to conduct the test could still be held liable. The 
narrow exceptions in GRDAA would have provided modest reforms 
while addressing the primary concerns of genetic sequence patenting 
by allowing broader access for genetic testing while still enforcing the 
patent holders’ rights in all other circumstances.294 
Compulsory licensing of human gene patents is another option 
that may balance the competing interests of the need to encourage 
companies to continue to pursue cutting edge research, protecting 
fundamental scientific principles, and providing maximum access to 
medical breakthroughs. Examples of compulsory licensing that could 
be utilized include: “march-in” rights under the Bayh-Doyle Act, 
refusal of injunctive relief under 35 U.S.C. §154(a)(1), and mandatory 
licensing under the Clean Air Act.
295
 
Congress could enact a type of compulsory license through 
“march-in rights” similar to the rights the federal government 
maintains under the Bayh-Doyle Act. March-in rights, like those 
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under the Bayh-Doyle Act, allow commercialization and public 
availability on federally funded inventions, which allows the 
government to “march in” and require a recipient of funds to license 
the invention under limited circumstances.
296
 The limited 
circumstances include underutilized technologies that have been 
developed through federally funded research.
297
 Since most basic 
research is aided by federal funds,
298
 some genetic sequence patents 
may already qualify for this type of protection. Expanding the 
government’s “march-in” rights to genetic sequence patents could 
solve several of the issues that patients currently face—lack of 
insurance coverage, prohibitive cost of the test, inability to obtain a 
second opinion, and quality control. This approach is not ideal 
because it lends itself to discretionary abuse. If enacted, the “march-in 
rights” provision would have to be narrowly tailored and carefully 
implemented in order to avoid abuse of discretion and overuse.
299
 
If the government enacts “march-in” rights, the patent owner 
would still need to be assured of reasonable compensation when those 
rights are exercised.
300
 One model of compulsory licensing through 
“reasonable compensation” is the Clean Air Act, which was enacted 
in the 1970s, and provided compulsory licenses for technologies 
related to air pollution prevention and control.
301
 A Clean Air Act 
compulsory license required that a patent that is critical to control air 
pollution must be compulsory licensed if the attorney general 
determines that the invention is not reasonably available, that there 
are no reasonable alternatives, and that the unavailability of the 
invention may result in a substantial problem of competition that 
would create a monopoly in the technology area.
302
 The application of 
a Clean Air Act like compulsory license would require the attorney 
general, or some other designated government entity, to determine if 
there was another way for the disease to be diagnosed, if the 
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unavailability of another diagnosis creates a significant problem to the 
public health, and the reasonableness of other alternatives. 
Additionally, a reasonable royalty would be set and distributed to any 
company found to qualify under this analysis. The threat of a 
compulsory license or “march-in” rights would influence companies 
to be more flexible in the licensing and access to their patents on 
genetic sequences, and would rarely need to be invoked considering 
most companies already provide reasonable access to genetic 
sequence patents. 
Court-implemented compulsory licenses could be enacted 
through a refusal by the court system to provide injunctive relief 
when infringement of a genetic sequence is found. Refusal to provide 
injunctive relief under 35 U.S.C. §154(a)(1) allows a court to order 
compulsory licensing if injunctive relief is improper when 
infringement is found.
303
 This method of compulsory licensing 
presents a problem because it is not a hard-line rule, so researchers 
and the public will not know when a court will deem the facts of their 
case to qualify for a compulsory license over injunctive relief. 
Injunctive relief bypasses a ruling that genes are unpatentable by 
taking the sting out of an infringement suit. 
5. Health Care Reform to Address Patient Access and 
Health Insurance Issues 
 The government at a state and federal level can institute 
insurance reform mandates that could require coverage of diagnostics 
tests.
304
 One of the key allegations in the ACLU’s complaint was that 
patients cannot get tested because they were either uninsured or their 
insurance would not cover the Myriad tests.
305
 A federal or state 
mandate requiring insurance coverage for genetic diagnostic tests 
                                                                                                                            
 303. Id. 
 304. See, e.g., Victoria Craig Bunce & J.P. Wieske, Health Insurance Mandates in the 
States 2010, COUNCIL FOR AFFORDABLE HEALTH INS. (Oct. 20, 2010), 
http://www.cahi.org/cahi_contents/resources/pdf/MandatesintheStates2010ExecSummary.pdf 
(summary of state mandate health insurance initiatives); id. at 8 (Summary of federal mandates 
in 2010). See generally The Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 
124 Stat. 119 (2010), available at http://www.gpo.gov/fdsys/pkg/PLAW-
111publ148/pdf/PLAW-111publ148.pdf. 
 305. Complaint, supra note 59, at 2 (“Many women at risk cannot even be tested because 
they are uninsured and/or cannot afford the test offered by Myriad”); see also id. at 10 (“Myriad 
will not accept the MassHealth Coverage”); see also id. at 12 (“Myriad would not accept her 
insurance”). 
18 JACOB (DO NOT DELETE) 3/28/2012  12:14 PM 
2012] SHOULD GENES BE PART OF PATENT BARGAIN 449 
 
when a doctor recommends the test would better solve this complaint 
than invalidation of genetic patents. Additionally, personal insurance 
mandates, as in Massachusetts, could require that every individual 
have health insurance, which would prevent uncovered individuals 
from accessing the technology. However, requiring insurance to cover 
the test or requiring an individual to carry health insurance would not 
ensure that a sole provider would accept that health insurance 
provider. In order to solve this issue, Congress would need to 
implement a requirement that health insurance cover diagnostic tests. 
Although this is an imperfect solution, it would have greater benefit 
than the invalidation of a patent, because even if there are two or 
more providers of a diagnostic test—it does not guarantee that any of 
the providers will accept all health insurance or that any of the health 
insurance providers will cover the test. 
Additionally, Congress, independent health care community 
regulators or the FDA could implement national standards that would 
address the manner in which the test is administered, the way in 
which the test is marketed, and the method in which the patient 
receives counseling after negative or positive results are received. 
In summary, there are several options to addressing patient 
access to diagnostic technologies. Patent invalidation will not broadly 
address all diagnostic technologies, which, regardless of subject 
matter, carry the same access and quality issues. In fact, patent 
invalidation will not guarantee that any of the access or care issues are 
addressed. Therefore, these issues should not be addressed through 
patent law, but through regulatory agencies and congressional 
legislation with the ability and foresight to craft much needed reforms 
in health care. 
D. Myriad Should Not Have Unfair Access to Medical Samples 
Based on Their Patents 
Some proponents of invalidating Myriad’s patent assert that 
Myriad’s patent allows the company “to collect annotated DNA 
samples that would give it an unfair advantage over potential 
competitors in discovering cures.”306 It could also give Myriad an 
unfair advantage in discovering other BRCA mutations, due to the 
large exclusive DNA sample size the company had immediate access 
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to.
307
 Effectively, this argument postulates that Myriad has a 
competitive advantage in the patenting of other BRCA mutations 
which could extend their monopoly. 
However, Myriad contends that they never intended to create a 
“private mutation database” and the company has extensively 
contributed new mutations to the Breast Cancer Information Core 
Mutation Database.
308
 There is some indication that they have already 
stopped contributing to the database and publishing articles,
309
 but 
this, like patient care and oversight of genetic testing, is not a patent 
issue. A patient’s tissue sample should not be placed into a “mutation 
bank” without informed consent. A patient’s autonomy necessitates 
that the conflicting interest of a company providing a medical test and 
the researcher trying to patent the next big invention should not 
cross.
310
 
First, to be placed in any type of “genetic mutation bank” a 
patient would first need to fully consent to sharing their medical 
information and tissue sample.
311
 An oversight committee could 
require all genetic tissue banks to secure patient consent before 
releasing information for research use, and that all information would 
then go into a nationally recognized database and not a privately held 
database. While a patent grants a negative right to a company to 
exclude others from practicing their invention, it does not provide a 
property right in an individual’s tissue sample. Legislation in genetic 
confidentiality, patient autonomy, and health care records is not a new 
area for Congress. Therefore, congressional legislation could easily 
extend to the creation and implementation of a national genetic 
database. Interestingly, if genetic sequences were ruled ineligible for 
patent protection, the likelihood of shared data might decrease due to 
the absence of a patent’s incentive to publicly disclose the research. 
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http://www.genomicslawreport.com/index.php/2011/03/01/how-will-myriad-respond-to-the-
next-generation-of-brca-testing/. 
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IX. CONCLUSION 
The patentability of genetic sequence is an interesting patent law 
query precisely because the arguments are strong on both sides. 
Patents are fundamental in the United States in order to further 
scientific research. Without the patent race, the expansive 
biotechnology sector would suffer. If patents on genetic sequences are 
held unpatentable, investors in biotechnology and medical diagnostics 
may worry that other types of biomedical patents will be excluded 
from the patent bargain in the future. Uncertainty in the 
biotechnology sector will have a negative impact on investments in 
research and development. Fundamentally, quality of patient care and 
access to diagnostic tests is a health care issue and patent law is not 
the solution. Myriad’s business practices essentially dictated how 
medical tests were distributed and regulated, how doctors were 
trained, how patients received results, patient access, and patient 
counseling. These are not issues for a private company or for patent 
law. Congress must ensure that patients are not treated at the whim of 
a company, but in a consistent and effectual manner that ensures 
quality access to healthcare and counseling afterwards. 
